Potentially harmful drug-drug interactions were highly prevalent (97.2%) among hospitalized cardiac patients, with the number of drugs taken and comorbid diabetes significantly predicting an increased number of interactions.
Cross-Sectional (n=215)
No
Potential drug-drug interactions are highly prevalent among hospitalized cardiac patients, particularly those with diabetes and polypharmacy, emphasizing the need for careful medication review.
Mean Difference: 0.562 (95% CI 0.468–0.655)
p-value: p=<0.001
BACKGROUND: Cardiovascular diseases are responsible for a significant proportion of mortalities worldwide. Elderly patients are the most affected by cardiovascular diseases, and because of factors such as polypharmacy, multimorbidity, and age-related changes in drug availability and metabolism, they are highly susceptible to the occurrence of drug-drug interactions. Drug-drug interactions are among the many drug-related problems leading to negative outcomes among inpatients and outpatients. Thus, it is important to investigate the prevalence, involved drugs, and factors related to potential drug-drug interactions (pDDIs) to properly optimize pharmacotherapy regimens for these patients. OBJECTIVE: We aimed to determine the prevalence of pDDIs, drugs most frequently implicated, and significant predictors associated with these interactions among hospitalized patients in the Cardiology Unit at Sultan Qaboos University Hospital in Muscat, Oman. METHODS: was used to identify pDDIs. Data extracted from patients' medical records were collected and analyzed. Univariable and multivariable linear regression was applied to determine the predictors associated with the observed pDDIs. RESULTS: A total of 2057 pDDIs were identified, with a median of nine (5-12) pDDIs per patient. Patients with at least one pDDI accounted for 97.2% of all the included patients. The majority of pDDIs were of major severity (52.6%), fair level of documentation (45.5%), and pharmacodynamic basis (55.9%). Potential drug-drug interactions between atorvastatin and clopidogrel were the most frequently observed (9%). Of all the detected pDDIs, around 79.6% of them included at least one antiplatelet drug. Having diabetes mellitus as a comorbidity (B = 2.564, p < 0.001) and the number of drugs taken during the hospitalization period (B = 0.562, p < 0.001) were factors positively associated with the frequency of pDDIs. CONCLUSIONS: Potential drug-drug interactions were highly prevalent among hospitalized cardiac patients at Sultan Qaboos University Hospital, Muscat, Oman. Patients having diabetes as a comorbidity and with a high number of administered drugs were at a higher risk of an increased number of pDDIs.
Kalash et al. (Sat,) conducted a cross-sectional in Cardiovascular diseases (n=215). Number of drugs taken was evaluated on Total number of potential drug-drug interactions (pDDIs) (B = 0.562, 95% CI 0.468-0.655, p=<0.001). Potentially harmful drug-drug interactions were highly prevalent (97.2%) among hospitalized cardiac patients, with the number of drugs taken and comorbid diabetes significantly predicting an increased number of interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: